12:00 AM
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vascular Targeting Agent regulatory update

TCLN received U.S. Patent No. 6,051,230 covering VTA compounds that deliver therapeutics by targeting tumor...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >